Double-blind, comparative study of milnacipran and paroxetine in Japanese patients with major depression

Kunitoshi Kamijima,1 Shinji Hashimoto,2 Eiichi Nagayoshi,2 Tsukasa Koyama3 1International University of Health and Welfare, Tochigi, 2Asahi-kasei Pharma Corporation, Tokyo, 3Ohyachi Hospital, Sapporo, Japan Background and methods: A double-blind, parallel-group, controlled study was performed to inv...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Kamijima K, Hashimoto S, Nagayoshi E, Koyama T
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2013
Materias:	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/27f580bcd7af457ea5a0eb5da9a45af0
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:27f580bcd7af457ea5a0eb5da9a45af0
record_format	dspace
spelling	oai:doaj.org-article:27f580bcd7af457ea5a0eb5da9a45af02021-12-02T05:57:13ZDouble-blind, comparative study of milnacipran and paroxetine in Japanese patients with major depression1176-63281178-2021https://doaj.org/article/27f580bcd7af457ea5a0eb5da9a45af02013-04-01T00:00:00Zhttp://www.dovepress.com/double-blind-comparative-study-of-milnacipran-and-paroxetine-in-japane-a12875https://doaj.org/toc/1176-6328https://doaj.org/toc/1178-2021Kunitoshi Kamijima,1 Shinji Hashimoto,2 Eiichi Nagayoshi,2 Tsukasa Koyama3 1International University of Health and Welfare, Tochigi, 2Asahi-kasei Pharma Corporation, Tokyo, 3Ohyachi Hospital, Sapporo, Japan Background and methods: A double-blind, parallel-group, controlled study was performed to investigate if milnacipran was noninferior to paroxetine in terms of improvement in symptoms of depression in Japanese patients with major depressive disorders in a fixed-dose design. The efficacy and safety of milnacipran 200 mg/day were also assessed in comparison with those at the standard dose of 100 mg/day. Results: Changes in 17-item Hamilton depression rating scale (HAM-D) total score (mean ± standard deviation) for group M1 (milnacipran 100 mg/day), group M2 (milnacipran 200 mg/day), and group PX (paroxetine 30 or 40 mg/day) were -12.9 ± 5.8, -12.8 ± 6.1, and -13.1 ± 6.2, respectively, and the estimated differences in total score for group PX (Dunnett's 95% simultaneous confidence interval) were 0.1 (-1.1 to 1.3) for group M1 and 0.3 (-0.9 to 1.5) for group M2. The noninferiority of groups M1 and M2 to group PX was thus confirmed, because the upper confidence limit of differences between groups M1 and PX and between groups M2 and PX was less than 2.0. The estimated mean difference of change in HAM-D total score (95% confidence interval) between groups M2 and M1 was 0.2 (-0.9 to 1.2), indicating a comparable change in total score for both groups. The incidence of treatment-related adverse events was 71.7% for group M1, 68.8% for group M2, and 69.3% for group PX, indicating no significant difference between the three groups. Conclusion: These results demonstrate that milnacipran 100 mg/day and 200 mg/day is not inferior to paroxetine in terms of efficacy and safety. Keywords: milnacipran, paroxetine, depression, noninferiority, JapanKamijima KHashimoto SNagayoshi EKoyama TDove Medical PressarticleNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol 2013, Iss default, Pp 555-565 (2013)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Kamijima K Hashimoto S Nagayoshi E Koyama T Double-blind, comparative study of milnacipran and paroxetine in Japanese patients with major depression
description	Kunitoshi Kamijima,1 Shinji Hashimoto,2 Eiichi Nagayoshi,2 Tsukasa Koyama3 1International University of Health and Welfare, Tochigi, 2Asahi-kasei Pharma Corporation, Tokyo, 3Ohyachi Hospital, Sapporo, Japan Background and methods: A double-blind, parallel-group, controlled study was performed to investigate if milnacipran was noninferior to paroxetine in terms of improvement in symptoms of depression in Japanese patients with major depressive disorders in a fixed-dose design. The efficacy and safety of milnacipran 200 mg/day were also assessed in comparison with those at the standard dose of 100 mg/day. Results: Changes in 17-item Hamilton depression rating scale (HAM-D) total score (mean ± standard deviation) for group M1 (milnacipran 100 mg/day), group M2 (milnacipran 200 mg/day), and group PX (paroxetine 30 or 40 mg/day) were -12.9 ± 5.8, -12.8 ± 6.1, and -13.1 ± 6.2, respectively, and the estimated differences in total score for group PX (Dunnett's 95% simultaneous confidence interval) were 0.1 (-1.1 to 1.3) for group M1 and 0.3 (-0.9 to 1.5) for group M2. The noninferiority of groups M1 and M2 to group PX was thus confirmed, because the upper confidence limit of differences between groups M1 and PX and between groups M2 and PX was less than 2.0. The estimated mean difference of change in HAM-D total score (95% confidence interval) between groups M2 and M1 was 0.2 (-0.9 to 1.2), indicating a comparable change in total score for both groups. The incidence of treatment-related adverse events was 71.7% for group M1, 68.8% for group M2, and 69.3% for group PX, indicating no significant difference between the three groups. Conclusion: These results demonstrate that milnacipran 100 mg/day and 200 mg/day is not inferior to paroxetine in terms of efficacy and safety. Keywords: milnacipran, paroxetine, depression, noninferiority, Japan
format	article
author	Kamijima K Hashimoto S Nagayoshi E Koyama T
author_facet	Kamijima K Hashimoto S Nagayoshi E Koyama T
author_sort	Kamijima K
title	Double-blind, comparative study of milnacipran and paroxetine in Japanese patients with major depression
title_short	Double-blind, comparative study of milnacipran and paroxetine in Japanese patients with major depression
title_full	Double-blind, comparative study of milnacipran and paroxetine in Japanese patients with major depression
title_fullStr	Double-blind, comparative study of milnacipran and paroxetine in Japanese patients with major depression
title_full_unstemmed	Double-blind, comparative study of milnacipran and paroxetine in Japanese patients with major depression
title_sort	double-blind, comparative study of milnacipran and paroxetine in japanese patients with major depression
publisher	Dove Medical Press
publishDate	2013
url	https://doaj.org/article/27f580bcd7af457ea5a0eb5da9a45af0
work_keys_str_mv	AT kamijimak doubleblindcomparativestudyofmilnacipranandparoxetineinjapanesepatientswithmajordepression AT hashimotos doubleblindcomparativestudyofmilnacipranandparoxetineinjapanesepatientswithmajordepression AT nagayoshie doubleblindcomparativestudyofmilnacipranandparoxetineinjapanesepatientswithmajordepression AT koyamat doubleblindcomparativestudyofmilnacipranandparoxetineinjapanesepatientswithmajordepression
_version_	1718400099472637952

Double-blind, comparative study of milnacipran and paroxetine in Japanese patients with major depression

Ejemplares similares